CO6721028A2 - Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina - Google Patents

Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina

Info

Publication number
CO6721028A2
CO6721028A2 CO13147309A CO13147309A CO6721028A2 CO 6721028 A2 CO6721028 A2 CO 6721028A2 CO 13147309 A CO13147309 A CO 13147309A CO 13147309 A CO13147309 A CO 13147309A CO 6721028 A2 CO6721028 A2 CO 6721028A2
Authority
CO
Colombia
Prior art keywords
synthesis
cyclopenta
isolation
trisodium salt
quinazoline
Prior art date
Application number
CO13147309A
Other languages
English (en)
Inventor
James Alan Kerschen
Alexander James Bridges
Milind D Choubal
Sean Mark Dalziel
Thomas Elliott Jacks
Andrew S Thompson
James Robert Zeller
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Publication of CO6721028A2 publication Critical patent/CO6721028A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/088General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing other elements, e.g. B, Si, As
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896Compounds having one or more Si-O-acyl linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

se proporciona 1- un nuevo método para la síntesis de L-glutamil-?- ácido D-glutámico y su uso en la síntesis de (2R)-((4S)-carboxi-4-(4, N-(((6S)-2-(hidroximetil)-4-oxo-3,4,7,8- tetrahidro-3H-ciclopenta[g] quinazolin-6-il)-N-(prop-2-inil)amino)benzamido) butanamido)pentanodioico. También se proporciona: 2- un método eficiente para el aislamiento y purificación de la sal trisódica del ácido arriba mencionado en una forma adecuada para almacena a largo plazo y su uso en una forma de dosificación parenteral.
CO13147309A 2010-12-22 2013-06-20 Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina CO6721028A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061459952P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
CO6721028A2 true CO6721028A2 (es) 2013-07-31

Family

ID=46314794

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13147309A CO6721028A2 (es) 2010-12-22 2013-06-20 Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina

Country Status (17)

Country Link
US (1) US9458188B2 (es)
EP (1) EP2655398B1 (es)
JP (1) JP2014513663A (es)
KR (1) KR20130132481A (es)
CN (1) CN103748106A (es)
AU (1) AU2011349551A1 (es)
BR (1) BR112013015600A2 (es)
CA (1) CA2819510A1 (es)
CO (1) CO6721028A2 (es)
DK (1) DK2655398T3 (es)
EA (1) EA201390635A1 (es)
HU (1) HUE028918T2 (es)
IL (1) IL226452A0 (es)
MX (1) MX2013007006A (es)
SG (1) SG191269A1 (es)
WO (1) WO2012087888A2 (es)
ZA (1) ZA201303821B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151398A (zh) * 2014-08-06 2014-11-19 四川同晟氨基酸有限公司 一种合成以谷氨酸为首个氨基酸残基二肽的方法
GB201707864D0 (en) * 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
CN107236021B (zh) * 2017-06-12 2020-12-01 湖北泓肽生物科技有限公司 一种多肽衍生物的合成方法
CA3078393A1 (en) * 2017-10-03 2019-04-11 Nissan Chemical Corporation Method for producing peptide compound
CA3133805A1 (en) * 2019-03-15 2020-09-24 Nissan Chemical Corporation Method for producing peptide compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827083D0 (en) * 1988-11-19 1988-12-21 Porton Prod Ltd Trialkylsilyl esters of amino acids & their use in synthesis of peptides
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
DK1420809T3 (da) * 2001-08-31 2011-12-19 Btg Int Ltd Anvendelse af cyclopenta[G]quinazolinderivater til behandling af cancer
ATE483722T1 (de) * 2001-08-31 2010-10-15 Btg Int Ltd Antikrebs-cyclopentaag chinazoline-derivate
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
ATE556715T1 (de) * 2008-03-18 2012-05-15 Btg Int Ltd Cyclopenta-äg-üchinazolin-derivate zur behandlung von arthritis oder akuter myeloischer leukämie

Also Published As

Publication number Publication date
EP2655398A2 (en) 2013-10-30
CA2819510A1 (en) 2012-06-28
US9458188B2 (en) 2016-10-04
CN103748106A (zh) 2014-04-23
DK2655398T3 (en) 2016-09-26
KR20130132481A (ko) 2013-12-04
SG191269A1 (en) 2013-07-31
WO2012087888A3 (en) 2014-03-06
ZA201303821B (en) 2014-04-30
EA201390635A1 (ru) 2014-09-30
MX2013007006A (es) 2013-07-30
JP2014513663A (ja) 2014-06-05
AU2011349551A1 (en) 2013-06-27
HUE028918T2 (en) 2017-01-30
EP2655398B1 (en) 2016-08-24
EP2655398A4 (en) 2015-06-17
US20130345423A1 (en) 2013-12-26
BR112013015600A2 (pt) 2018-05-22
IL226452A0 (en) 2013-07-31
WO2012087888A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
CO6721028A2 (es) Acoplamientos eficientes de péptido y su uso en la síntesis y aislamiento de una sal trisódica de ciclopenta (g) quinazolina
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
PH12014501277A1 (en) Kinase inhibitors
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
EA201070786A1 (ru) Бензофуропиримидиноны
TN2011000293A1 (en) Protein kinase inhibitors
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
RS54653B1 (en) 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
PE20191655A1 (es) Combinaciones farmaceuticas
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
IL220665A0 (en) Pyruvamide compounds as inhibitors of dust time group 1 peptidase allergen and their use
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
PT2707003T (pt) Sais cristalinos da amida do ácido (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetra-hidroxi-7-[(metoxi(metil)amino]-metil]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octa-hidro-naftaceno-2-carboxílico e métodos de utilização dos mesmos
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors